CRISPR Therapeutics Series B

CRISPR Therapeutics is a Swiss-American biotechnology company focused on translating CRISPR/Cas9 gene-editing technology into transformative medicines for serious diseases. They develop cures for genetic diseases by precisely modifying DNA, with a diverse portfolio including treatments for hemoglobinopathies, oncology, and regenerative medicine. Their lead program, exagamglogene autotemcel (exa-cel), has received regulatory approval in several countries for sickle cell disease and transfusion-dependent beta thalassemia.